(Q41107174)

26 September 2017

1 reference

title

Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection (English)

1 reference

26 September 2017

1 reference

S Noble

1

1 reference

26 September 2017

D Faulds

series ordinal

2

1 reference

26 September 2017

language of work or name

1 reference

1 July 1996

1 reference

26 September 2017

1 reference

26 September 2017

52

1 reference

26 September 2017

1

1 reference

26 September 2017

93-112

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-199652010-00007

26 September 2017

0 references

cites work

Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group

1 reference

12 December 2020

In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors

1 reference

12 December 2020

Other AIDS drug regimens beat AZT alone, reduce clinical progression and mortality

1 reference

12 December 2020

Current knowledge and future prospects for the use of HIV protease inhibitors

1 reference

12 December 2020

Rational design of peptide-based HIV proteinase inhibitors

1 reference

12 December 2020

Reduced sensitivity to saquinavir: an update on genotyping from phase I/II trials

1 reference

12 December 2020

Identification of an amino acid substitution involved in the reduction of sensitivity of HIV-1 to an inhibitor of viral proteinase.

1 reference

12 December 2020

New drugs for HIV infection

1 reference

12 December 2020

Didanosine. A review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection

1 reference

12 December 2020

Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors

1 reference

12 December 2020

Surrogate markers in AIDS: where are we? Where are we going?

1 reference

12 December 2020

HIV therapy advances. Update on a proteinase inhibitor

1 reference

12 December 2020

A bend in the road--implications of ACTG 175 and Delta trials

1 reference

12 December 2020

Drug-resistance patterns of saquinavir and other HIV proteinase inhibitors

1 reference

12 December 2020

Progression of early steps of human immunodeficiency virus type 1 replication in the presence of an inhibitor of viral protease

1 reference

12 December 2020

Treatment options in zidovudine intolerance or failure

1 reference

12 December 2020

Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro

1 reference

12 December 2020

Safety and activity of saquinavir in HIV infection

1 reference

12 December 2020

HIV therapy advances. Early antiretroviral therapy

1 reference

12 December 2020

HTLV-III gag protein is processed in yeast cells by the virus pol-protease

1 reference

12 December 2020

The immunopathogenesis of human immunodeficiency virus infection

1 reference

12 December 2020

Pathogenesis of human immunodeficiency virus infection

1 reference

12 December 2020

Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1

1 reference

12 December 2020

Inter-Company Collaboration Combination Trials. Clinical Trial Subcommittee of the Inter-Company Collaboration for AIDS Drug Development

1 reference

12 December 2020

Managing HIV disease after Delta

1 reference

12 December 2020

Modeling the relationship between survival and CD4 lymphocytes in patients with AIDS and AIDS-related complex

1 reference

12 December 2020

Resistance of HIV type 1 to proteinase inhibitor Ro 31-8959.

1 reference

12 December 2020

CD4+ lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine

1 reference

12 December 2020

Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase

1 reference

12 December 2020

Zalcitabine. A review of its pharmacology and clinical potential in acquired immunodeficiency syndrome (AIDS)

1 reference

12 December 2020

Human immunodeficiency virus type 1 (HIV-1) inhibitory interactions between protease inhibitor Ro 31-8959 and zidovudine, 2',3'-dideoxycytidine, or recombinant interferon-alpha A against zidovudine-sensitive or -resistant HIV-1 in vitro

1 reference

12 December 2020

Saquinavir/zidovudine combination in patients with advanced HIV infection and no prior antiretroviral therapy: CD4+ lymphocyte/plasma RNA changes, and emergence of HIV strains with reduced phenotypic sensitivity.

1 reference

12 December 2020

The inhibition of human immunodeficiency virus type 1 in vitro by a non-nucleoside reverse transcriptase inhibitor MKC-442, alone and in combination with other anti-HIV compounds

1 reference

12 December 2020

Inhibition of human immunodeficiency virus type 1 replication in cytokine-stimulated monocytes/macrophages by combination therapy

1 reference

12 December 2020

Combinative interactions of a human immunodeficiency virus (HIV) Tat antagonist with HIV reverse transcriptase inhibitors and an HIV protease inhibitor

1 reference

12 December 2020

Active human immunodeficiency virus protease is required for viral infectivity

1 reference

12 December 2020

In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease

1 reference

12 December 2020

Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959.

1 reference

12 December 2020

CD4 Count and the Risk for Death in Patients Infected with HIV Receiving Antiretroviral Therapy

1 reference

12 December 2020

10.2165/00003495-199652010-00007

Identifiers

DOI

1 reference

Dimensions Publication ID

26 September 2017

0 references

1 reference